Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 24, Issue 15, 2014, Pages 3234-3237

  Yun, Jun ^a,c   Han, Minsoo ^a   Song, Chiman ^a   Cheon, Seung Hoon ^b   Choi, Kihang ^c   Hahn, Hoh Gyu ^a  

^a Korea Institute of Science and Technology   (South Korea)

^b Chonnam National University   (South Korea)

^c Korea University   (South Korea)

Author keywords

3 Phenethylazetidines; Antidepressant; Depression; Triple reuptake inhibitor

Indexed keywords

3 PHENETHYLAZETIDINE DERIVATIVE; ANTIDEPRESSANT AGENT; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DOPAMINE; DULOXETINE; FLUOXETINE; MIBEFRADIL; NISOXETINE; NOREPHEDRINE; POTASSIUM CHANNEL HERG; SEROTONIN; TRIPLE REUPTAKE INHIBITOR; UNCLASSIFIED DRUG; VANOXERINE; VENLAFAXINE; 3-(2-(4-CHLORO-3-FLUOROPHENYL)-2-(3-FLUOROPHENOXY)ETHYL)AZETIDINE; AZETIDINE DERIVATIVE; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; DIPHENYL ETHER DERIVATIVE; NEUROTRANSMITTER UPTAKE INHIBITOR; PLASMA MEMBRANE NEUROTRANSMITTER TRANSPORTER; ALDEHYDE; ALUMINUM LITHIUM HYDRIDE; DOPAMINE TRANSPORTER; NORADRENALIN TRANSPORTER; SEROTONIN TRANSPORTER;

ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; ENZYME INHIBITION; EVALUATION STUDY; GRIGNARD REACTION; HUMAN; HUMAN CELL; IC 50; MITSUNOBU REACTION; SWERN OXIDATION; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TRANSPORT AT THE CELLULAR LEVEL; BIOLOGICAL ACTIVITY; CARBON NUCLEAR MAGNETIC RESONANCE; CHROMATOGRAPHY; DEPRESSION; DRUG SCREENING; HIGH THROUGHPUT SCREENING; IC50; PROTON NUCLEAR MAGNETIC RESONANCE;

AZETIDINES; BIOLOGICAL TRANSPORT; CYTOCHROME P-450 ENZYME INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; MOLECULAR STRUCTURE; NEUROTRANSMITTER UPTAKE INHIBITORS; PHENYL ETHERS; PLASMA MEMBRANE NEUROTRANSMITTER TRANSPORT PROTEINS; SEROTONIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84904065583     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2014.06.026     Document Type: Article

References (21)

1. S.K. Kulkarni, and A. Dhir Expert Opin. Investig. Drugs 18 2009 767
2. M.J. Millan Pharmacol. Ther. 110 2006 135
3. B. Perović, M. Jovanović, B. Miljković, and S. Vezmar Neuropsychiatr. Dis. Treat. 6 2010 343
4. J. Prins, B. Olivier, and S.M. Korte Expert Opin. Investig. Drugs 20 2011 1107
5. G.I. Papakostas, J.J. Worthington III, D.V. Iosifescu, G. Kinrys, A.M. Burns, L.B. Fisher, C.H. Homberger, D. Mischoulon, and M. Fava Depression Anxiety 23 2006 178
6. L.C. Daws Pharmacol. Ther. 121 2009 89
7. C. Costagliola, F. Parmeggiani, F. Semeraro, and A. Sebastiani Curr. Neuropharmacol. 6 2008 293
8. M. Vaswani, F.K. Linda, and S. Ramesh Prog. Neuropsychopharmacol. Biol. Psychiatry 27 2003 85
9. S. Zisook, A.J. Rush, B.R. Haight, D.C. Clines, and C.B. Rockett Biol. Psychiatry 59 2006 203
10. C. Prica, M. Hascoet, and M. Bourin Behav. Brain Res. 194 2008 92
11. Z. Chen, and P. Skolnick Expert Opin. Investig Drugs 16 2007 1365
12. M.J. Millan Neurotherapeutics 13 2009 53
13. Y. Liang, and E. Richelson Primary Psychiatry 15 2008 50
14. P. Skolnick, P. Popik, A. Janowsky, B. Beer, and A.S. Lippa Life Sci. 73 2003 3175
15. P. Skolnick, P. Krieter, J. Tizzano, A. Basile, P. Popik, P. Czobor, and A. Lippa CNS Drug Rev. 12 2006 123
16. P. Skolnick, P. Popik, A. Janowsky, B. Beer, and A.S. Lippa Eur. J. Pharmacol. 461 2003 99
17. L. Shao, W. Li, Q. Xie, and H. Yin Expert Opin. Ther. Pattents 24 2014 131
18. Y. Han, M. Han, D. Shin, C. Song, and H.-G. Hahn J. Med. Chem. 55 2012 8188
19. A. Duranti, C. Franchini, G. Lentini, F. Loiodice, V. Tortorella, A.D. Luca, S. Pierno, and D.C. Camerino Eur. J. Med. Chem. 30 2000 147
20. D.T. Collin, D. Hartley, D. Jack, L.H.C. Lunts, J.C. Press, A.C. Ritchie, and P. Toon J. Med. Chem. 13 1970 674
21. S. Jørgensen, E.O. Nielsen, D. Peters, and T. Dyhring J. Neurosci. Methods 169 2008 168.